Table 4.

Survival analyses by subgroups for gastric cancer patients according to the Cox proportional hazards model

	High MMP14a			Positive nuclear PROX1a
	HR	95% CI	P value	HR	95% CI	P value
Age, y
<67	1.56	0.95‐2.56	.081	0.63	0.39‐1.02	.060
≥67	1.23	0.80‐1.90	.349	0.94	0.61‐1.44	.775
Gender
Male	1.55	0.95‐2.54	.082	0.61	0.38‐0.98	.043
Female	1.33	0.86‐2.06	.196	1.02	0.67‐1.56	.930
Stage
I	0.93	0.10‐8.31	.947	1.36	0.23‐8.15	.738
II	1.73	0.77‐3.90	.185	0.96	0.42‐2.09	.870
III	1.39	0.87‐2.23	.166	0.84	0.53‐1.32	.448
IV	1.25	0.70‐2.25	.447	0.98	0.56‐1.72	.938
Tumor classification (pT)
pT1	1.65	0.17‐15.9	.666	2.43	0.25‐23.4	.442
pT2	0.55	0.12‐2.53	.443	0.71	0.21‐2.36	.576
pT3	1.74	1.04‐2.92	.036	0.60	0.35‐1.03	.066
pT4	1.03	0.65‐1.64	.892	1.07	0.70‐1.64	.763
Lymph node metastasis (pN)
pN0	1.63	0.74‐3.55	.223	0.47	0.21‐1.06	.068
pN1‐3	1.52	1.06‐2.20	.025	1.02	0.71‐1.45	.931
Distant metastasis (pM)
pM0	1.51	1.02‐2.23	.042	0.74	0.50‐1.08	.116
pM1	1.25	0.70‐2.25	.447	0.98	0.56‐1.72	.938
Laurén classification
Intestinal	1.37	0.77‐2.43	.286	0.72	0.40‐1.29	.266
Diffuse	1.44	0.97‐2.14	.072	0.76	0.52‐1.12	.165
MMP14a
Low				0.89	0.60‐1.30	.538
High				0.67	0.39‐1.18	.166
Serum MMP14
Low	1.42	0.94‐2.15	.099	0.77	0.51‐1.15	.200
High	1.42	0.63‐3.23	.401	0.83	0.39‐1.79	.637
Cytoplasmic PROX1a
Low	1.53	1.07‐2.18	.020	1.03	0.72‐1.46	.889
High	1.19	0.48‐2.91	.711	0.60	0.25‐1.43	.247
Nuclear PROX1a
Negative	1.65	1.09‐2.51	.019
Positive	1.21	0.71‐2.06	.487

Abbreviations: CI, confidence interval; HR, hazard ratio; MMP14, matrix metalloproteinase 14; PROX1, prospero homeobox protein 1

^aBy immunohistochemistry.